Skip to main content
Premium Trial:

Request an Annual Quote

If It's Worth Doing, It's Worth Doing Right (FDA, That Means You)

A Wall Street Journal article reports on Harvard professor Daniel Carpenter, who is defending research indicating that the US FDA made "overly hasty approval decisions on medicines," now that FDA has criticized the research as flawed. Evidently, the original study did have mistakes -- but Carpenter says that coincides with errors in the FDA's own records. He says that "after he made necessary corrections, his original finding still held: Drugs that the FDA has approved soon before a regulatory deadline have been more likely to develop severe safety problems later on," according to the article.


The Scan

Rise of BA.5

The New York Times reports that the Omicron subvariant BA.5 has become the dominant version of SARS-CoV-2 in the US.

UK Health Secretary Resigns

Sajid Javid, the UK health secretary, resigned along with Chancellor Rishi Sunak, saying they cannot work with Prime Minister Boris Johnson's government, CNN reports.

Clones From Freeze-Dried Cells

A team in Japan has cloned mice from freeze-dried skin cells, according to the Guardian.

Genome Research Papers on Craniosynostosis, Macaque Retrotransposition, More

In Genome Research this week: structural variants in craniosynostosis, LINE-1 activity in rhesus macaque brain, and more.